Protein Phosphatase 6 Activates NF-κB to Confer Sensitivity to MAPK Pathway Inhibitors in KRAS- and BRAF-Mutant Cancer Cells

To better understand the genetic pathways that modulate cancer cell sensitivity to Ras–mitogen-activated protein kinase (MAPK) pathway inhibitors, scientists performed a CRISPR knockout screen with MAPK pathway inhibitors on a colorectal cancer cell line carrying mutant KRAS.